Our Mission
We help healthcare providers deliver safer diagnostic imaging by eliminating the risk of contrast-induced nephropathy (CIN) through our revolutionary non-nephrotoxic IV contrast agent.
About Nuvira
Our Founder
Sahaj Satani saw the need for safer medical imaging during his volunteer and research work at medical facilities. He set out to create a solution that eliminates nephrotoxic risks for patients with kidney concerns.
Our story
What began as a research project aimed at preventing contrast-induced nephropathy has grown into a groundbreaking effort to develop safe, kidney-friendly contrast agents for diagnostic scans.
By focusing on safety without compromising diagnostic quality, we are transforming how medical imaging serves those most at risk.
Why?
Market Growth
Contrast media market to reach $7.88 billion by 2030, growing at 3.7% CAGR.
Chronic Diseases
Increasing prevalence of conditions requiring diagnostic imaging drives market expansion.
Aging Population
Growing elderly demographic fuels demand for advanced medical imaging technologies.
Safety Concerns
CIN affects up to 25% of high-risk patients, highlighting need for safer alternatives.
2
5
Patent Applications
Research Projects
Planned Clinical Trials
8
